Glenmark Pharmaceutical to invest in new translational research group at Biopôle Lausanne-Epalinges

Glenmark Pharmaceutical to invest in new translational research group at Biopôle Lausanne-Epalinges

La Chaux-de-Fonds, Switzerland & Paramus, N.J. – Glenmark Pharmaceuticals announced today it will enhance its capabilities in translational research by opening a new discovery centre at the Biopôle campus of Lausanne. Glenmark will continue to invest in, and operate its process development and biologics manufacturing centre out of La-Chaux-de-Fonds, Neuchȃtel. Approximately 20% of current employees will be housed in the discovery group at Lausanne.
Source: Glenmark Pharmaceuticals (Press Release)

About the author

Amitabh Arora

Amitabh Arora

Amitabh Arora has more than 18 years of experience promoting foreign direct investments (FDI), trade and economic relations between India and Switzerland, South Korea, United Kingdom and Canada. He is currently working as Director Key Accounts at the Greater Geneva Berne area (GGBa), the economic development agency of western Switzerland. GGBa offers a comprehensive range of services at no charge to foreign companies seeking to establish a presence in Switzerland. He is also the founder of FDITracker.com, tracking FDI developments worldwide. Amitabh has a Masters in International Business from the Indian Institute of Foreign Trade (IIFT) and a Bachelor of Business Studies (BBS) from College of Business Studies, India.

    Leave a Reply